OSII-TTP: Adjuvant High-Dose Thiotepa and Stem Cell Rescue Associated With Conventional Chemotherapy in Relapsed Osteosarcoma

Sponsor

Centre Leon Berard (Other)

Overall Status

Completed

CT.gov ID

NCT00978471

Collaborator

(none)

Enrollment

Locations

Arms

111.9

Duration (Months)

1.9

Patients Per Site

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Approximately 150 new cases of osteosarcoma are reported each year in France, of which 15 to 20% are metastatic.

Further to the initial standard care, about 45% of the patients relapse within a median duration of 20 months.

Result of the OS94 study results and of the investigation performed within the CRLCC, indicate that 25 to 30 patients (children and adults) experience an osteosarcoma relapse each year in FRANCE.

According to several studies, the 5-year overall survival rate of patients in first relapse is 23-28%,with a median post relapse survival of 10 to 17 months. Multiple relapse cases are also reported in the COSS study, with a median time to second relapse of 0.8 year.

At present, there is no reference treatment for the standard care of osteosarcoma relapse in FRANCE.

Thiotepa is known for its antitumor effect in numerous malignant tumors. In 2007, a study from our institution reported that about 35% of all osteosarcoma relapses are treated with a high-dose thiotepa while the efficacy and tolerance of this therapeutic strategy have never been assessed.

These results highlight the need to the evaluate the efficacy and tolerance of this high-dose of thiotepa within a clinical trial and its inclusion in the standard care of the osteosarcoma at relapse.

Condition or Disease	Intervention/Treatment	Phase
Osteosarcoma	Drug: Thiotepa	Phase 2

Detailed Description

Despite the absence of tumor registry, approximately 150 new cases of osteosarcoma are reported each year in France (100 cases per year in children and 50 cases in adults), of which 15 to 20% are metastatic. The standardized impact rate in the world population is estimated at 3 per million inhabitants per year.

Further to the initial standard care, about 45% of the patients relapse within a median interval of 20 months (range 3 months - 10 years).

Results of the OS94 study and of the investigation performed within the CRLCC indicate that 25 to 30 patients (children and adults) experience an osteosarcoma relapse each year in FRANCE.

Results of the five major published series indicate that the 5-year overall survival rate of patients in first relapse is between 23 and 28%, with a median post-relapse survival of 10 to 17 months. Multiple relapse cases are also reported in the COSS study, with a median time to second relapse of 0.8 year.

At present, there is no reference treatment for the standard care of osteosarcoma relapse in FRANCE.

Some recommendations have been given in the OS94 protocol, but they are generally not followed or they are implemented in a heterogeneous manner.

Thiotepa (N N' N'' triethylenethiophosphoramide), an alkylating agent of the chemical family of ethylene-imines, is known for its antitumor effect in a number of malignant tumors.

Its efficacy in osteosarcoma has been reported in the literature. A retrospective study of the SFCE (French Society for Childhood Cancer, results not yet published) in 45 patients presenting with refractory osteosarcoma or relapse has shown a radiological reaction rate of 30%.

Moreover, a preliminary investigation performed by the CLB in 2007 within the framework of the SFCE study explored all relapse cases diagnosed between the beginning of 2004 and the end of 2006. Results showed that about 35% of the patients with osteosarcoma relapses are treated with high-dose thiotepa while the efficacy and tolerance of this therapeutic strategy have never been assessed.

Altogether, these results led the SFCE osteosarcoma group to propose the evaluation of the efficacy and tolerance of this high-dose thiotepa chemotherapy within a clinical trial and to include the drug in the standard care of osteosarcoma in relapse.

Study Design

Study Type:

Interventional

Actual Enrollment :

44 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

Efficacy and Tolerance Adjuvant High-Dose Thiotepa With Peripheral Stem Cell Rescue Associated With Conventional Chemotherapy in Children and Adults With Relapsed Osteosarcoma

Study Start Date :

Jul 1, 2009

Actual Primary Completion Date :

Oct 29, 2018

Actual Study Completion Date :

Oct 29, 2018

Arms and Interventions

Arm	Intervention/Treatment
Experimental: experimental arm thiotepa 4 courses of conventional chemotherapy followed by high-dose Thiotepa with peripheral stem cell rescue. Surgical resection of all tumor masses will be performed as soon as possible.	Drug: Thiotepa Thiotepa 8-12mg/m²/day/injection Total dose for one cure:15-50mg. Other Names: N N'N'triethylenethiophosphosphoramide Tepadina
Other: Reference arm 4 courses of conventional chemotherapy. Surgical resection of all tumor masses will be performed as soon as possible.	Drug: Thiotepa Thiotepa 8-12mg/m²/day/injection Total dose for one cure:15-50mg. Other Names: N N'N'triethylenethiophosphosphoramide Tepadina

Arm

Intervention/Treatment

Experimental: experimental arm thiotepa

4 courses of conventional chemotherapy followed by high-dose Thiotepa with peripheral stem cell rescue. Surgical resection of all tumor masses will be performed as soon as possible.

Drug: Thiotepa

Thiotepa 8-12mg/m²/day/injection Total dose for one cure:15-50mg.

Other Names:

N N'N'triethylenethiophosphosphoramide

Tepadina

Other: Reference arm

4 courses of conventional chemotherapy. Surgical resection of all tumor masses will be performed as soon as possible.

Drug: Thiotepa

Thiotepa 8-12mg/m²/day/injection Total dose for one cure:15-50mg.

Other Names:

N N'N'triethylenethiophosphosphoramide

Tepadina

Outcome Measures

Primary Outcome Measures

Estimate the overall survival rate [24 months]

Secondary Outcome Measures

Estimate overall survival after relapse diagnosis [24 months]
Estimate the survival free progression after randomization [24 months]
Evaluate the tolerance profile of experimental treatment (hematologic toxicity) [every 3 weeks]
Estimate the rate of tumor response to treatment as assessed by conventional CT-scan [at inclusion, day 14-day 21 after the 2nd chemotherapy cycle, before randomization, day 14-day 21 after the 4th chemotherapy cycle, after thiotepa cure and 8 weeks after the end of treatment]
Estimate histological response to treatment on surgical tumor samples [If surgery is applicable, a few weeks after thiotepa cure (12 to 17 weeks after inclusion)]
Study of biological and genomic properties and analysis of angiogenic markers correlated with relapse (optional) [At inclusion,at surgery , and at the end of treatment]

Eligibility Criteria

Criteria

Ages Eligible for Study:

1 Year to 50 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Age > 1 year and < 50 years
First osteosarcoma relapse, either local or metastatic, or second relapse after exclusive surgery NB: Whenever possible, only patients with histological evidence of relapse will be included.
Indication for chemotherapy confirmed by a multidisciplinary committee.
Surgical resection of all tumor sites must be possible, either as first-line therapy or after chemotherapy.
Lansky score ≥ 60%, or ECOG Performance Status ≤ 2
≥ 21-day interval after first-line chemotherapy
Blood tests, renal and liver functions within the normal range for age with, in particular, 7 days prior to study entry, blood or serum values as follows:
blood: neutrophil count > 1 G/L; platelets >100 G/L
renal: serum creatinine ≤ 1.5 x ULN depending on age; patients with serum creatinine values > 1.5 x ULN are eligible if creatinine clearance is > 70 mL/min/1.73 m²
liver: total bilirubin < 2 x ULN; ASAT and ALAT ≤ 5 x ULN
cardiac: isotopic or echographic Left Ventricular Ejection Fraction > 50 %.
Signed written informed consent; for children, signed consent from the patient (depending on age) and from the parents or legal representative is mandatory
Documented negative serum βHCG for female patients of childbearing age
Affiliation with health insurance.

Exclusion Criteria:

Patients with multiple relapses for whom surgical resection seems impossible, even after chemotherapy.
Patients already treated with high-dose chemotherapy regimens
Patients with a contra-indication to the treatment proposed
Patients not eligible for leukapheresis
Two-year follow-up impossible due to social, family, geographic or psychological reasons
Patient included in another protocol of clinical research
Pregnant or lactating women.

Contacts and Locations

Locations

	Site	City	Country	Postal Code
1	CHU Besançon- Hôpital Jean Minjoz	Besancon	France	25000
2	Chu - Hopital Des Enfants Bordeaux	Bordeaux	France	33000
3	CHU Dijon Le Bocage, Hôpital d'Enfants	Dijon	France	21079
4	Chu Grenoble	Grenoble	France	38045
5	Centre Oscar Lambret	Lille	France	59000
6	Centre Léon Bérard - Institut d'Hémato-Oncologie Pediatrique	LYON Cedex 08	France	69373
7	Institut Paoli Calmettes	Marseille	France	13273
8	Hôpital des Enfants de la Timone	Marseille	France	13385
9	Chu Nantes - Hopital Meres Et Enfants	Nantes	France	44093
10	Centre Antoine Lacassagne	Nice	France	06189
11	CHU Nice, Hôpital L'Archet 2	Nice	France	06202
12	Institut Curie	Paris	France	75248
13	Hopital D'Enfants Armand Trousseau	Paris	France	75571
14	CHU Poitiers, site de la Milétrie	Poitiers	France	86021
15	CHU RENNES - Hôpital Sud	Rennes	France	35023
16	CHU de SAINT-ETIENNE, Hôpital Nord	Saint Priest en Jarez	France	42270
17	Chu La Reunion	Saint-denis	France	97405
18	Institut de Cancérologie de l'Ouest - René Gauducheau	Saint-herblain	France	44805
19	Institut Lucien Neurwith	Saint-Priest-en -Jarez	France	42270
20	Hopital de Hautepierre	Strasbourg	France	67098
21	Chu Toulouse - Hopital D'Enfants	Toulouse	France	31059
22	Chu Nancy - Hopital D'Enfants	Vandoeuvre Les Nancy	France	54511
23	Institut Gustave Roussy	Villejuif	France	95805